Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.Donate to our crowdfunder
To ask the Secretary of State for Health, if he will take steps to ensure that palbociclib is made available to all eligible breast cancer patients.
Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is currently appraising Palbociclib in combination with an aromatase inhibitor for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults. NICE published its draft guidance on 3 February and stakeholders have until 24 February to comment on its draft recommendations. NICE expects to publish its final guidance in June 2017.